Clarithromycin

• Respiratory Tract Infections
• Helicobacter pylori Eradication
• Community-Acquired Pneumonia
• Mycobacterial Infections

Clarithromycin is a macrolide antibiotic used to treat a wide variety of bacterial infections. This medication is particularly important in respiratory tract infections and is a key component of Helicobacter pylori eradication therapy for peptic ulcer disease.

Mechanism of Action

Clarithromycin exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Specifically, it blocks the translocation step where the growing peptide chain moves from the A-site to the P-site of the ribosome. This action is primarily bacteriostatic, though it can be bactericidal at high concentrations or against highly susceptible organisms. Clarithromycin has activity against many Gram-positive bacteria (streptococci, staphylococci), some Gram-negative bacteria (Hemophilus influenzae, Moraxella catarrhalis), and atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella). It also has activity against Helicobacter pylori and some mycobacteria.

Available Formulations

Clarithromycin is available as immediate-release tablets (250 mg, 500 mg), extended-release tablets (500 mg), and oral suspension (125 mg/5 mL, 250 mg/5 mL). The immediate-release formulation can be taken with or without food, though taking with food may reduce gastrointestinal upset. Extended-release tablets should be taken with food. The suspension should be shaken well before each use and can be taken with or without food.

Medical Uses

Clarithromycin is FDA-approved for pharyngitis/tonsillitis, acute maxillary sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated skin and skin structure infections, and disseminated mycobacterial infections. It is also a critical component of combination therapy for H. pylori eradication. The extended-release formulation is approved for acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, and community-acquired pneumonia.

Dosing Guidelines

For most infections in adults, the typical dose is 250-500 mg twice daily for 7-14 days. For H. pylori eradication, 500 mg twice daily is used in combination with a proton pump inhibitor and amoxicillin or metronidazole for 10-14 days. The extended-release formulation is dosed at 1000 mg once daily for 7 days. Pediatric dosing is typically 7.5 mg/kg twice daily (maximum 500 mg per dose). Dose reduction is required for severe renal impairment (CrCl less than 30 mL/min): reduce dose by 50% or double the dosing interval.

Important Safety Information

Clarithromycin is contraindicated in patients with known hypersensitivity to macrolides. It is also contraindicated with certain medications due to QT prolongation risk (pimozide, cisapride) and significant CYP3A4 interactions (ergot derivatives, lovastatin, simvastatin). QT prolongation and ventricular arrhythmias have been reported; use with caution in patients with cardiac disease or electrolyte abnormalities. Hepatotoxicity, including hepatic failure, has occurred. Clostridioides difficile-associated diarrhea may occur.

Drug Interactions

Clarithromycin is a potent CYP3A4 inhibitor with numerous significant drug interactions. It increases levels of many medications including statins (contraindicated with lovastatin/simvastatin), calcium channel blockers, carbamazepine, theophylline, and digoxin. Colchicine toxicity has been reported; dose reduction is required. Concurrent use with other QT-prolonging medications increases arrhythmia risk. Clarithromycin levels are increased by ritonavir and decreased by rifampin.

Choosing Clarithromycin Over Other Antibiotics

Clarithromycin is seldom a first choice for routine outpatient infection, and the reason is resistance rather than efficacy. Pneumococcal resistance to macrolides is high enough across much of the United States that a macrolide alone is not relied on for pneumonia in a patient with comorbid illness or recent antibiotic exposure; it is used as part of combination therapy or reserved for patients in whom a beta-lactam is not an option. For uncomplicated sinusitis and for acute bronchitis, most cases are viral and need no antibiotic at all, and when one is indicated amoxicillin or amoxicillin-clavulanate is the usual first agent. Doxycycline covers the atypical pathogens without the interaction burden described above and is often preferred in penicillin-allergic adults, while azithromycin offers shorter dosing and far fewer CYP3A4 problems, which is why it displaced clarithromycin for most respiratory indications.

Where clarithromycin retains a distinct role is H. pylori infection. Even there, rising macrolide resistance has moved clarithromycin-based triple therapy out of the automatic first-line position, and current gastroenterology guidance favors bismuth-based quadruple regimens when local resistance is high or the patient has had any prior macrolide exposure. Confirming eradication after treatment, rather than assuming it, is now standard. The National Institute of Diabetes and Digestive and Kidney Diseases explains the link between the organism and peptic ulcer disease.

The Interaction Review That Happens Before the First Dose

Clarithromycin is one of the few outpatient antibiotics whose interaction profile can be more dangerous than the infection. The full medication list is reviewed before the prescription is written, not after a problem appears. Simvastatin and lovastatin are stopped or the antibiotic changed, because the combination causes rhabdomyolysis. Colchicine requires dose reduction or interruption, and fatal toxicity has occurred when it was not adjusted. Warfarin, digoxin, and certain calcium channel blockers all rise, and the resulting bleeding, bradycardia, or hypotension typically appears several days into the course. Older adults on multiple QT-prolonging drugs are the group in whom an alternative antibiotic is usually the safer answer. The MedlinePlus clarithromycin monograph lists the patient-facing warnings, and our gastrointestinal team selects the eradication regimen with prior antibiotic exposure in mind.

Special Populations

Clarithromycin should be avoided during pregnancy if possible due to potential fetal harm observed in animal studies. It is excreted in breast milk; use with caution during breastfeeding. Safety and efficacy have been established in pediatric patients 6 months and older for most indications. Elderly patients may be more susceptible to QT prolongation and drug interactions. Dose adjustment is required for severe renal impairment. Clarithromycin is extensively hepatically metabolized; use with caution in hepatic impairment.